论文部分内容阅读
患者被确诊为癌症后,决定其命运的是癌转移。美国国立癌症研究所(NCI)病理实验室肿瘤侵袭与转移研究部主任L.A.Liotla博士和他的助手们,正从事癌转移前制止它们出现癌扩散的三项新课题的研究。研究中最令人鼓舞的一种称为NM-23的细胞因子,它在肿瘤细胞中的消失高度预示着预后不良;NM-23还被证实既可作为肿瘤标记物,又可用于治疗。第二种新发现是名为TIMP-22的蛋白,它能抑制癌的侵袭和血管生成。第三项研究
After a patient is diagnosed with cancer, it is cancer metastasis that determines its fate. Dr. L.A. Liotla, director of the Department of Tumor Invasion and Metastasis Research at the National Cancer Institute’s (NCI) Pathology Laboratory, and his assistants are working on three new topics to prevent cancer from spreading before cancer metastasis. One of the most inspiring cytokines known as NM-23, whose disappearance in tumor cells is highly predictive of poor prognosis; NM-23 has also been shown to serve both as a tumor marker and as a treatment. The second new discovery is the protein called TIMP-22, which inhibits cancer invasion and angiogenesis. The third study